Ardent Health remains a 'buy' as shares are deeply undervalued despite recent profitability declines. ARDT revenue continues to grow, with management projecting $6.4–$6.7 billion for the year, but EBITDA and cash flow are expected to fall short of prior results. Professional fees pressured margins, but management anticipates this cost trend will moderate in the second half, signaling potential stabilization.
Investors need to pay close attention to ARDT stock based on the movements in the options market lately.
Investors need to pay close attention to ARDT stock based on the movements in the options market lately.
ARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026.
Ardent Health NYSE: ARDT reported second-quarter revenue of $1.62 billion and adjusted EBITDA of $115 million, as management said cost controls, a favorable payer contract renewal and strong cash flow helped offset weaker-than-expected volumes.
Ardent Health, Inc. (ARDT) Q2 2026 Earnings Call Transcript
Ardent Health, Inc. (ARDT) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.52 per share a year ago.
Ardent Health, Inc. (ARDT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to ARDT stock based on the movements in the options market lately.
Ardent Health, Inc. (ARDT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Ardent Health, Inc. (ARDT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ardent Health, Inc. (ARDT) Q1 2026 Earnings Call Transcript